Company: IPSC
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001104659-25-037419
Chunk: 46

Company: Century Therapeutics, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 46
---
 of iPSC-derived therapies for the treatment of inflammatory and autoimmune diseases, or the Autoimmune License. In addition, the Company and FCDI entered into an amendment to each of the Reprogramming License and the Differentiation License to expand the licenses related to the development and commercialization of IPSC-derived cancer immunotherapeutic to also include inflammatory and autoimmune diseases. Under the terms of these agreements, FCDI will be eligible to receive certain development and regulatory milestone payments as well as low single-digit royalties related to products developed in connection with such agreements. In consideration of entering into the Autoimmune License and amending each of the Reprogramming License and Differentiation License, we made an upfront payment to FCDI in the amount of $4.0 million. In addition, we paid FCDI a $1.0 million milestone fee pursuant to the Autoimmune License for filing of the IND for SLE for CNTY-101. There were no payments made under the Autoimmune License in 2024. Letter Agreement On January 7, 2022, we and FCDI entered into a letter agreement, or the Letter Agreement, in connection with the Company’s former collaboration with Bristol-Myers Squibb Company, or BMS, which amended the Reprogramming License and the Differentiation License such that (i) the definition of Territory under each for purposes of the sublicenses includes Japan, (ii) the licenses granted to us and our affiliates under the Reprogramming License and the Differentiation License were sublicensable to BMS, including with respect to Japan and (iii) BMS was not subject to grant-back and option provisions under the Reprogramming License. Pursuant to the Letter Agreement, and in consideration for amending the Reprogramming License and the Differentiation License, we (i) paid to FCDI an upfront payment of $10 million. No payments were made under the Letter Agreement in 2023 or 2024. Executive Officer and Director Compensation Please see “Executive Compensation” and “Director Compensation” for information regarding the compensation of our directors and executive officers. Employment Agreements We have entered into employment agreements or offer letter agreements with certain of our executive officers that, among other things, provide for certain compensatory and change in control benefits, as well as severance benefits. Notice of Annual Meeting of Stockholders and 2025 Proxy Statement | 29

TABLE OF CONTENTS

| ​ | CERTAIN RELATIONSHIPS AND RELATED PARTYTRANSACTIONS | ​